-+ 0.00%
-+ 0.00%
-+ 0.00%

Celldex reports Phase 2 data showing barzolvolimab retreatment restores strong efficacy in cold urticaria and symptomatic dermographism

Reuters·03/01/2026 14:45:15

Please log in to view news